ACTRN12624000665538尚未招募2 期
Efficacy and tolerability of tirzepatide in the management of obesity in potential kidney transplant candidates with end-stage kidney disease: a pilot study
St Vincent's Hospital Melbourne0 个研究点目标入组 8 人开始时间: 2024年5月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •18 years or older at the time of enrolment
- •Obesity (body mass index [BMI] of 30 kg/m2 or above)
- •ESKD, requiring haemodialysis, at the time of enrolment
- •Considered a potential candidate for kidney transplantation
- •Can provide informed consent
排除标准
- •Previous or planned (during the trial period) bariatric surgery
- •Type 1 diabetes
- •History of acute or chronic pancreatitis
- •Personal or first-degree relative history of multiple endocrine neoplasia type 2 or medullary Thyroid carcinoma
- •Proliferative diabetic retinopathy requiring acute treatment
- •Pregnancy, lactation, or plan to become pregnant within 28 weeks of enrolment
- •Known hypersensitivity to tirzepatide
研究者
相似试验
招募中
Unknown
A Study on the Safety and Efficacy of Tirzepatide in People with Type 2 DiabetesType 2 DiabetesJPRN-UMIN000052214Kitasato University50
招募中
Unknown
Clinical Study on the Efficacy of Tirzepatide for Diabetes Complicated ObesityJPRN-UMIN000054143Sekino Hospital10
招募中
Unknown
The efficacy and safety of Tirzepatide for type 2 diabetes subjects with chronic kidney disease: prospective observational studyType 2 diabetesJPRN-UMIN000051344Kushiro Red Cross Hospital50
进行中（未招募）
3 期
Participants without Type 2 Diabetes who are Overweight.CTRI/2020/04/024660Eli Lilly and Company India Pvt Ltd
进行中（未招募）
3 期
Effect of Tirzepatide versus Placebo in Participants with Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2)Participants with type 2 diabetes who have obesity or are overweightJPRN-jRCT2031200440Masaki Takeshi64